HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW Market Executive Decisions: Unilever’s Next CEO, CRN Staff, GOED Board, PLZ CEO

Executive Summary

Unilever names Schumacher as Jope’s successor at CEO; specialty aerosol, liquid products firm PLZ appoints CEO; GOED seats 2023 board officers; and CRN adds and promotes staff members.

You may also be interested in...



Euro Q3 Consumer Health Earnings Preview: Helm Changes, Investor Questions, Results Debut

Major Europe-based consumer health players Reckitt, Bayer, Sanofi and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2022 results over the coming weeks.

CRN Promotes Counsel, Marketing And Regulatory Directors, Adds Legal, Communications Staff

Megan Olsen moves up to general counsel/senior VP, Gretchen Powers to marketing/member experience VP, Haiuyen Nguyen to regulatory/nutrition policy VP and Tammie Betway to office director/executive assistant to president/CEO. CRN also adds Daniel Garza as legislative/legal assistant and Elise Hall as communications assistant.

Unilever Announces Corporate Restructuring Amid Reports Of Activist Investor Influence

Around 1,500 senior and junior management roles will be cut under Unilever’s announced plan to reshape its corporate matrix, the firm reports on 25 January. The news comes a day after reports that activist investor Nelson Peltz of Trian Fund Management has taken a stake in the business.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153332

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel